A cellular automaton model for tumor dormancy: Emergence of a proliferative switch

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Chen, Duyu ^a   Jiao, Yang ^a,b   Torquato, Salvatore ^a,c  

^a PRINCETON UNIVERSITY   (United States)

^b Arizona State University   (United States)

^c Princeton University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL; CANCER CONTROL; CANCER INHIBITION; CELL COUNT; CELL DIVISION; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; DISEASE ACTIVITY; DORMANCY; GROWTH RATE; HOST CELL; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PREDICTION; PROBABILITY; SOLID TUMOR; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; CELL TRANSFORMATION; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84908052327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109934     Document Type: Article

References (61)

1. Almog N (2010) Molecular mechanisms underlying tumor dormancy. Cancer Lett 294: 139-146.
2. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846.
3. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
4. Karrison TG, Ferguson DJ, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer I 91: 80-85.
5. Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, Mclaughlin PO, et al. (2006) Telomerase activity in disseminated prostate cancer cells. BJU Int 97: 1309-1313.
6. Weckermann D, Müller P, Wawroschek F, Harzmann R, Riethmüller G, et al. (2001) Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol 166: 699-704.
7. Aguirre-Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and mapk signaling. J Cell Biol 147: 89-104.
8. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, et al. (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer I 98: 316-325.
9. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, et al. (2003) Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Tr 82: 199-206.
10. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK (2004) Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 64: 7336-7345.
11. Kusumbe AP, Bapat SA (2009) Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69: 9245-9253.
12. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353.
13. Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis. Semin Cancer Biol 19: 329-337.
14. Krahenbuhl JL, Lambert Jr LH, Remington JS (1976) The effects of activated macrophages on tumor target cells: escape from cytostasis. Cell Immunol 25: 279-293.
15. Weinhold KJ, Goldstein LT, Wheelock E (1979) The tumor dormant state. Quantitation of l5178y cells and host immune responses during the establishment and course of dormancy in syngeneic dba/2 mice. J Exp Med 149: 732-744.
16. Matsuzawa A, Takeda Y, Narita M, Ozawa H (1991) Survival of leukemic cells in a dormant state following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (dl811). Int J Cancer 49: 303-309.
17. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.
18. Finn OJ (2006) Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res 36: 73-82.
19. Uhr JW, Scheuermann RH, Street NE, Vitetta ES (1997) Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 3: 505-509.
20. Marches R, Scheuermann R, Uhr J (2006) Cancer dormancy from mice to man: A review. Cell Cycle 5: 1772-1778.
21. Quesnel B (2008) Dormant tumor cells as a therapeutic target? Cancer Lett 267: 10-17.
22. Byrne HM (2010) Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer 10: 221-230.
23. Burton AC (1966) Rate of growth of solid tumours as a problem of diffusion. Growth 30: 157-176.
24. Greenspan H (1972) Models for the growth of a solid tumor by diffusion. Stud Appl Math 51: 317-340.
25. Owen MR, Byrne HM, Lewis CE (2004) Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. J Theor Biol 226: 377-391.
26. Smallbone K, Gavaghan DJ, Gatenby RA, Maini PK (2005) The role of acidity in solid tumour growth and invasion. J Theor Biol 235: 476-484.
27. Jiang Y, Pjesivac-Grbovic J, Cantrell C, Freyer JP (2005) A multiscale model for avascular tumor growth. Biophys J 89: 3884-3894.
28. Quaranta V, Rejniak KA, Gerlee P, Anderson AR (2008) Invasion emerges from cancer cell adaptation to competitive microenvironments: quantitative predictions from multiscale mathematical models. Semin. Cancer Biol. 18: 338-348.
29. Anderson AR (2005) A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math Med Biol 22: 163-186.
30. Kim Y, Stolarska MA, Othmer HG (2007) A hybrid model for tumor spheroid growth in vitro i: theoretical development and early results. Math Mod Meth Appl S 17: 1773-1798.
31. Page K, Uhr J (2005) Mathematical models of cancer dormancy. Leukemia Lymphoma 46: 313-327.
32. Kuznetsov VA, Knott GD (2001) Modeling tumor regrowth and immunotherapy. Math Comput Model 33: 1275-1287.
33. Lefever R, Horsthemke W (1979) Bistability in fluctuating environments. implications in tumor immunology. Bull Math Biol 41: 469-490.
34. De Angelis E, Lods B (2008) On the kinetic theory for active particles: A model for tumor-immune system competition. Math Comput Model 47: 196-209.
35. Brazzoli I, De Angelis E, Jabin PE (2010) A mathematical model of immune competition related to cancer dynamics. Math Methods Appl Sci 33: 733-750.
36. Bellomo N, Delitala M (2008) From the mathematical kinetic, and stochastic game theory to modelling mutations, onset, progression and immune competition of cancer cells. Phys Life Rev 5: 183-206.
37. Takayanagi T, Kawamura H, Ohuchi A (2006) Cellular automaton model of a tumor tissue consisting of tumor cells, cytotoxic t lymphocytes (ctls), and cytokine produced by ctls. Inf Media Technol 1: 780-786.
38. Kansal A, Torquato S, Harsh Iv G, Chiocca E, Deisboeck T (2000) Cellular automaton of idealized brain tumor growth dynamics. Biosystems 55: 119-127.
39. Schmitz JE, Kansal AR, Torquato S (2002) A cellular automaton model of brain tumor treatment and resistance. Comput Math Methods M 4: 223-239.
40. Torquato S (2011) Toward an ising model of cancer and beyond. Phys Biol 8: 015017.
41. Jiao Y, Torquato S (2011) Emergent behaviors from a cellular automaton model for invasive tumor growth in heterogeneous microenvironments. PLoS Comput Biol 7: e1002314.
42. Jiao Y, Torquato S (2012) Diversity of dynamics and morphologies of invasive solid tumors. AIP Adv 2: 011003-011003.
43. Torquato S (2002) Random heterogeneous materials: microstructure and macroscopic properties: Springer-Verlag.
44. Jiao Y, Torquato S (2013) Evolution and morphology of microenvironment-enhanced malignancy of three-dimensional invasive solid tumors. Phys Rev E 87: 052707.
45. Saudemont A, Quesnel B (2004) In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 104: 2124-2133.
46. Bos PD, Rudensky AY (2012) Treg cells in cancer: a case of multiple personality disorder. Sci Transl Med 4: 164fs44-164fs44.
47. Blatner NR, Mulcahy MF, Dennis KL, Scholtens D, Bentrem DJ, et al. (2012) Expression of rorct marks a pathogenic regulatory t cell subset in human colon cancer. Sci Transl Med 4: 164ra159-164ra159.
48. Hoffman HJ, Becker L, Craven M (1980) A clinically and pathologically distinct group of benign brain stem gliomas. Neurosurgery 7: 243-248.
49. Mahaley Jr MS, Mettlin C, Natarajan N, Laws Jr ER, Peace BB (1989) National survey of patterns of care for brain-tumor patients. J Neurosurg 71: 826-836.
50. England DM, Hochholzer L, McCarthy MJ (1989) Localized benign and malignant fibrous tumors of the pleura: a clinicopathologic review of 223 cases. Am J Surg Pathol 13: 640-658.
51. Seewaldt V (2014) ECM stiffness paves the way for tumor cells. Nat Med 20: 332-333.
52. Kleffel S, Schatton T (2013) Tumor dormancy and cancer stem cells: two sides of the same coin? Adv Exp Med Biol 734: 145-179.
53. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R et al. (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400-404.
54. Kloxin AM, Tibbitt MW, Kasko AM, Fairbairn JA, Anseth KS (2010) Tunable hydrogels through controlled photodegradation for external manipulation of the cell microenvironment. Adv Mater 22: 61-66.
55. Barkan D, Green JE (2011) An in vitro system to study tumor dormancy and the switch to metastatic growth. J Vis Exp 54: e2914.
56. Chaterjee M, van Golen KL (2011) Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy. Bone Marrow Res 2011: 362938.
57. Wells A, Griffith L, Wells JZ, Taylor DP (2013) The dormancy dilemma: quiescence versus balanced proliferation. Cancer Res 73: 1-6.
58. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, et al. (2012) The cd47-signal regulatory protein alpha (sirpa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U.S.A. 109: 6662-6667.
59. Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, et al. (2010) Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 70: 5706-5716.
60. Klein CA (2013) Selection and adaptation during metastatic cancer progression. Nature 501: 365-372.
61. Wu A, Liao D, Tlsty TD, Sturm JC, Austin RH (2014) Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment. Interface Focus 4: 20140028.